Arthur Vranken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arthur Vranken has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Maarten Naesens
Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven, Leuven, Belgium
4 shared publications - Thibaut Vaulet
Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
4 shared publications - Karolien Wellekens
Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
3 shared publications - Maarten Coemans
Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
3 shared publications - Priyanka Koshy
Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
3 shared publications - Aiko P. J. de Vries
Leiden Transplant Center, Leiden University Medical Center, Leiden, the Netherlands
2 shared publications
Latest Publications
- Open Access
Continuous Diagnostic Indices from BanffNET Automated Lesion Scores for Kidney Transplant Pathology: Development and Evaluation of a Diagnostic Prediction Model
Background: Histopathological diagnoses in kidney transplant biopsies, as described by the Banff classification, suffer from substantial inter-observer variability and misinterpretation, making them prone to diagnostic errors. Continuous indices based on BanffNET automated lesion scores are proposed to quantify the continuous phenotypic spectrum of kidney transplant biopsies, complementary to pathologist assessment of biopsies. Methods: The BanffNET model was used to obtain continuous lesion scoring for a training cohort of 2544 biopsies, a large validation cohort of 3863 biopsies, and a multi-reader cohort of 36 biopsies scored by 67 pathologists. A penalized regression approach was used to condense 17 automated lesion scores into four indices, representing the most important dimensions of graft injury: a TCMR/TI Index, an AMR/MVI Index, an Activity Index and a Chronicity Index. The BanffNET Indices were evaluated against Banff diagnoses and histological indices in the training cohort and validation cohort. Since pathologist-assigned Banff lesions and diagnoses suffer from inter-observer variability, associations were also assessed with diagnoses in a multi-reader study, with time to kidney graft failure in the training and validation cohort and with biopsy-based molecular signatures in the validation cohort. Results: The BanffNET TCMR/TI Index, AMR/MVI Index and Activity Index showed excellent discrimination of Banff TCMR, Banff MVI and Banff Any Diagnosis respectively, with validation AUCs ranging from 0.80 to 0.92. In addition, the BanffNET Indices explained large amounts of variability in multi-observer reference standards, time to graft failure and molecular biopsy-based diagnostics. In the large majority of cases, variability explained by BanffNET Indices matched or exceeded the variability explained by pathologist-assigned diagnoses and histological indices. Conclusions: BanffNET Indices are reproducible descriptors of whole slide images that could complement and augment kidney transplant biopsy evaluation by pathologists. Associations of BanffNET Indices with multi-observer diagnoses and related outcomes suggest that they capture additional information on tissue injury type and severity on top of pathologist-assigned Banff diagnoses and histological indices.
Open AccessContinuous Diagnostic Indices from BanffNET Automated Lesion Scores for Kidney Transplant Pathology: Development and Evaluation of a Diagnostic Prediction Model
Background: Histopathological diagnoses in kidney transplant biopsies, as described by the Banff classification, suffer from substantial inter-observer variability and misinterpretation, making them prone to diagnostic errors. Continuous indices based on BanffNET automated lesion scores are proposed to quantify the continuous phenotypic spectrum of kidney transplant biopsies, complementary to pathologist assessment of biopsies. Methods: The BanffNET model was used to obtain continuous lesion scoring for a training cohort of 2544 biopsies, a large validation cohort of 3863 biopsies, and a multi-reader cohort of 36 biopsies scored by 67 pathologists. A penalized regression approach was used to condense 17 automated lesion scores into four indices, representing the most important dimensions of graft injury: a TCMR/TI Index, an AMR/MVI Index, an Activity Index and a Chronicity Index. The BanffNET Indices were evaluated against Banff diagnoses and histological indices in the training cohort and validation cohort. Since pathologist-assigned Banff lesions and diagnoses suffer from inter-observer variability, associations were also assessed with diagnoses in a multi-reader study, with time to kidney graft failure in the training and validation cohort and with biopsy-based molecular signatures in the validation cohort. Results: The BanffNET TCMR/TI Index, AMR/MVI Index and Activity Index showed excellent discrimination of Banff TCMR, Banff MVI and Banff Any Diagnosis respectively, with validation AUCs ranging from 0.80 to 0.92. In addition, the BanffNET Indices explained large amounts of variability in multi-observer reference standards, time to graft failure and molecular biopsy-based diagnostics. In the large majority of cases, variability explained by BanffNET Indices matched or exceeded the variability explained by pathologist-assigned diagnoses and histological indices. Conclusions: BanffNET Indices are reproducible descriptors of whole slide images that could complement and augment kidney transplant biopsy evaluation by pathologists. Associations of BanffNET Indices with multi-observer diagnoses and related outcomes suggest that they capture additional information on tissue injury type and severity on top of pathologist-assigned Banff diagnoses and histological indices.
- 14 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (10) , 2262-2274
Clinical Relevance of Donor-Derived cfDNA In Monitoring Kidney Transplant Rejection
Background: Over the past 25 years, donor-derived cell-free DNA (dd-cfDNA) has emerged as a noninvasive biomarker for detecting allograft rejection in kidney transplant recipients, yet its clinical interpretability and context(s) of use in post-transplant monitoring remain largely unexplored. Methods: In this observational cohort study, we analyzed 472 retrospective and 450 prospective plasma samples as the derivation and validation cohorts, respectively. Samples were collected at the time of either an indication or a protocol kidney biopsy. We evaluated three logistic regression models for rejection discrimination: a clinical model, the dd-cfDNA alone, and their combination. Result-specific likelihood ratios (LR) were derived from the dd-cfDNA-based model probabilities and applied to the clinical model predictions to obtain post-test probabilities of rejection. By comparing pre- and post-test probabilities, we assessed the impact of dd-cfDNA on rejection risk stratification. Results: Dd-cfDNA alone demonstrated strong discriminative ability, with AUCs of 0.79 (95% CI: 0.73–0.84) and 0.80 (95% CI: 0.72–0.87) in the derivation and validation cohorts, respectively. Combining dd-cfDNA with clinical parameters improved the above AUCs to 0.82 and 0.87, respectively. We compared pre- and post-test probabilities to determine how dd-cfDNA testing influenced rejection risk estimation. Incorporating dd-cfDNA-testing results clarified risk stratification by reducing the number of samples categorized as intermediate (10-30%) pre-test risk. Overall, 253/345 pre-test intermediate risk samples were reclassified, with 117/162 (72%) and 33/91 (36%) correctly assigned to low (≤10%) and high (≥30%) post-test risk, respectively. With 10% probability threshold for warranting a kidney biopsy, 482 biopsies would have been safely avoided using post-test probabilities, with 437 (91%) of these being protocol biopsies. Conclusions: Our study confirmed the strong association between dd-cfDNA% and rejection after kidney transplantation. Using test result-specific likelihood ratio, we evaluated the impact of integrating dd-cfDNA% for estimating time-point-specific rejection risk, demonstrating its potential to reduce the number of unnecessary biopsies in a cohort with a relatively low rejection prevalence.
- 14 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (10) , 2262-2274
Clinical Relevance of Donor-Derived cfDNA In Monitoring Kidney Transplant Rejection
Background: Over the past 25 years, donor-derived cell-free DNA (dd-cfDNA) has emerged as a noninvasive biomarker for detecting allograft rejection in kidney transplant recipients, yet its clinical interpretability and context(s) of use in post-transplant monitoring remain largely unexplored. Methods: In this observational cohort study, we analyzed 472 retrospective and 450 prospective plasma samples as the derivation and validation cohorts, respectively. Samples were collected at the time of either an indication or a protocol kidney biopsy. We evaluated three logistic regression models for rejection discrimination: a clinical model, the dd-cfDNA alone, and their combination. Result-specific likelihood ratios (LR) were derived from the dd-cfDNA-based model probabilities and applied to the clinical model predictions to obtain post-test probabilities of rejection. By comparing pre- and post-test probabilities, we assessed the impact of dd-cfDNA on rejection risk stratification. Results: Dd-cfDNA alone demonstrated strong discriminative ability, with AUCs of 0.79 (95% CI: 0.73–0.84) and 0.80 (95% CI: 0.72–0.87) in the derivation and validation cohorts, respectively. Combining dd-cfDNA with clinical parameters improved the above AUCs to 0.82 and 0.87, respectively. We compared pre- and post-test probabilities to determine how dd-cfDNA testing influenced rejection risk estimation. Incorporating dd-cfDNA-testing results clarified risk stratification by reducing the number of samples categorized as intermediate (10-30%) pre-test risk. Overall, 253/345 pre-test intermediate risk samples were reclassified, with 117/162 (72%) and 33/91 (36%) correctly assigned to low (≤10%) and high (≥30%) post-test risk, respectively. With 10% probability threshold for warranting a kidney biopsy, 482 biopsies would have been safely avoided using post-test probabilities, with 437 (91%) of these being protocol biopsies. Conclusions: Our study confirmed the strong association between dd-cfDNA% and rejection after kidney transplantation. Using test result-specific likelihood ratio, we evaluated the impact of integrating dd-cfDNA% for estimating time-point-specific rejection risk, demonstrating its potential to reduce the number of unnecessary biopsies in a cohort with a relatively low rejection prevalence.
- Open Access
- 25 March 2026
- Published by Springer Nature in Research Square
Cytomegalovirus Infection Determines Microvascular Inflammation Risk beyond Alloimmunity in Kidney Transplantation
Microvascular inflammation (MVI) is a major determinant of kidney allograft failure, yet its upstream drivers remain incompletely defined. Natural killer (NK) cells contribute to donor-specific antibody (DSA)-positive and DSA-negative MVI via antibody-dependent cytotoxicity and missing-self recognition. Cytomegalovirus (CMV) infection durably remodels the NK cell compartment, inducing memory-like populations with heightened effector function. In a contemporary multicenter cohort of 4,411 kidney transplants with 10,214 post-transplant biopsies in the CMV prophylaxis era, CMV seropositivity, indicative of prior infection, was independently associated with a twofold higher hazard of MVI and increased graft failure. This association extended across antibody-mediated and DSA-negative, C4d-negative MVI and acted synergistically with HLA-DSA and missing self. Post-transplant CMV replication and disease were associated with subsequent MVI only in seronegative recipients, consistent with an effect of primary CMV infection. Together, these findings identify CMV infection as a clinically relevant and previously underrecognized determinant of MVI, beyond alloimmune factors.
- 25 March 2026
- Published by Springer Nature in Research Square
Open AccessCytomegalovirus Infection Determines Microvascular Inflammation Risk beyond Alloimmunity in Kidney Transplantation
Microvascular inflammation (MVI) is a major determinant of kidney allograft failure, yet its upstream drivers remain incompletely defined. Natural killer (NK) cells contribute to donor-specific antibody (DSA)-positive and DSA-negative MVI via antibody-dependent cytotoxicity and missing-self recognition. Cytomegalovirus (CMV) infection durably remodels the NK cell compartment, inducing memory-like populations with heightened effector function. In a contemporary multicenter cohort of 4,411 kidney transplants with 10,214 post-transplant biopsies in the CMV prophylaxis era, CMV seropositivity, indicative of prior infection, was independently associated with a twofold higher hazard of MVI and increased graft failure. This association extended across antibody-mediated and DSA-negative, C4d-negative MVI and acted synergistically with HLA-DSA and missing self. Post-transplant CMV replication and disease were associated with subsequent MVI only in seronegative recipients, consistent with an effect of primary CMV infection. Together, these findings identify CMV infection as a clinically relevant and previously underrecognized determinant of MVI, beyond alloimmune factors.
- Open Access
Repeated histological diagnoses and kidney graft failure: an observational cohort study
A bstract: Background: Banff histological diagnoses do not capture how a graft’s injury has evolved over time. Repeated injury is common, but the consequences of repeated histological injury are currently not known, especially when observed in the absence of clinical signs. Methods: In a single-center observational cohort of 1818 kidney transplantations performed between 2004 and 2021, with 5218 post-transplant biopsies of which 82% were pre-planned protocol biopsies, transitions between six Banff histological diagnoses were described as recurrent events, with landmark Aalen-Johansen estimates and unadjusted Andersen-Gill rate ratios. A multistate model, with states for a first and a second diagnosis of rejection-related injury (RRI, comprising TCMR, AMR and MVI DSA-/C4d- ), estimated cause-specific hazards of death-censored graft failure, in all biopsies and in protocol biopsies only. Follow-up ran from day 90 to five years after transplantation. Results: Each diagnosis was more frequent after an earlier episode of the same diagnosis, and several diagnoses also made a different diagnosis more or less frequent: TCMR was more frequent after AMR, MVI DSA-/C4d- and BKPyVAN, and AMR less frequent after MVI DSA-/C4d- . The hazard of graft failure was increased after a first RRI diagnosis (HR 2.18, 95% CI 1.35–3.51) and substantially further after a second (HR 9.31, 95% CI 5.84–14.85). The association persisted when both diagnoses were made on protocol biopsy, in the absence of clinical signs (HR 1.76, 95% CI 1.09–2.84 and HR 2.58, 95% CI 1.31–5.08), although the difference between a second and a first diagnosis was not statistically significant. Conclusions: A prior Banff diagnosis strongly predicts that same diagnosis recurring, and in several cases also changes the expected incidence of a different diagnosis. A second diagnosis of rejection-related injury identifies a markedly higher-risk graft than a first, independently of baseline risk factors, and subclinical episodes detected on protocol biopsy also mark increased risk. This defines both an unmet therapeutic need and a high-risk population for trial enrichment. K ey learning points: What was known: A Banff diagnosis is rendered from a single biopsy, yet alloimmune injury often persists, recurs or changes over time. Repeated T-cell mediated rejection adds risk of graft failure, but evidence comes almost entirely from indication biopsies. How other diagnoses recur, and whether one predicts another, was largely unknown. This study adds: In 1818 transplants with 5218 biopsies (82% protocol), a prior diagnosis strongly predicted its recurrence and altered the incidence of others. A second rejection-related episode carried a significantly higher hazard of death-censored graft failure than a first (9.31 versus 2.18). Subclinical protocol-biopsy episodes also carried risk (2.58 versus 1.76). Potential impact: A first episode marks a graft at elevated risk, not a resolved problem. Biopsies are best read alongside the graft’s diagnostic history. Protocol biopsies detect prognostically relevant injury in apparently well recipients. Recipients with a second episode form a high-risk group suited to trials of more durable immune modulation.
Open AccessRepeated histological diagnoses and kidney graft failure: an observational cohort study
A bstract: Background: Banff histological diagnoses do not capture how a graft’s injury has evolved over time. Repeated injury is common, but the consequences of repeated histological injury are currently not known, especially when observed in the absence of clinical signs. Methods: In a single-center observational cohort of 1818 kidney transplantations performed between 2004 and 2021, with 5218 post-transplant biopsies of which 82% were pre-planned protocol biopsies, transitions between six Banff histological diagnoses were described as recurrent events, with landmark Aalen-Johansen estimates and unadjusted Andersen-Gill rate ratios. A multistate model, with states for a first and a second diagnosis of rejection-related injury (RRI, comprising TCMR, AMR and MVI DSA-/C4d- ), estimated cause-specific hazards of death-censored graft failure, in all biopsies and in protocol biopsies only. Follow-up ran from day 90 to five years after transplantation. Results: Each diagnosis was more frequent after an earlier episode of the same diagnosis, and several diagnoses also made a different diagnosis more or less frequent: TCMR was more frequent after AMR, MVI DSA-/C4d- and BKPyVAN, and AMR less frequent after MVI DSA-/C4d- . The hazard of graft failure was increased after a first RRI diagnosis (HR 2.18, 95% CI 1.35–3.51) and substantially further after a second (HR 9.31, 95% CI 5.84–14.85). The association persisted when both diagnoses were made on protocol biopsy, in the absence of clinical signs (HR 1.76, 95% CI 1.09–2.84 and HR 2.58, 95% CI 1.31–5.08), although the difference between a second and a first diagnosis was not statistically significant. Conclusions: A prior Banff diagnosis strongly predicts that same diagnosis recurring, and in several cases also changes the expected incidence of a different diagnosis. A second diagnosis of rejection-related injury identifies a markedly higher-risk graft than a first, independently of baseline risk factors, and subclinical episodes detected on protocol biopsy also mark increased risk. This defines both an unmet therapeutic need and a high-risk population for trial enrichment. K ey learning points: What was known: A Banff diagnosis is rendered from a single biopsy, yet alloimmune injury often persists, recurs or changes over time. Repeated T-cell mediated rejection adds risk of graft failure, but evidence comes almost entirely from indication biopsies. How other diagnoses recur, and whether one predicts another, was largely unknown. This study adds: In 1818 transplants with 5218 biopsies (82% protocol), a prior diagnosis strongly predicted its recurrence and altered the incidence of others. A second rejection-related episode carried a significantly higher hazard of death-censored graft failure than a first (9.31 versus 2.18). Subclinical protocol-biopsy episodes also carried risk (2.58 versus 1.76). Potential impact: A first episode marks a graft at elevated risk, not a resolved problem. Biopsies are best read alongside the graft’s diagnostic history. Protocol biopsies detect prognostically relevant injury in apparently well recipients. Recipients with a second episode form a high-risk group suited to trials of more durable immune modulation.